Global Dendritic Cell Cancer Vaccine Sales Market Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Dendritic Cell Cancer Vaccine Sales Market Report 2024
Market Analysis and InsightsGlobal Dendritic Cell Cancer Vaccine Market
Dendritic cells (DCs) refer to rare kind of leukocytes. They have prompted their recent application to therapeutic cancer vaccinations as they are uniquely effective in their ability to present antigens to T cells.
Due to the COVID-19 pandemic, the global Dendritic Cell Cancer Vaccine market size is estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034. Fully considering the economic change by this health crisis, CreaVax accounting for % of the Dendritic Cell Cancer Vaccine global market in 2024, is projected to value US$ million by 2034, growing at a revised % CAGR from 2023 to 2034. While Pediatrics segment is altered to an % CAGR throughout this forecast period.
The United States Dendritic Cell Cancer Vaccine market is estimated at US$ million in 2024, while China was US$ million. The proportion of the United States is % in 2024, while Chinese percentage was %, and it is predicted that China share will reach % in 2034, trailing a CAGR of % through the analysis period.
The global key manufacturers of Dendritic Cell Cancer Vaccine include Activarti, Argos Therapeutics, SOTIO (Acquired by PPF Group), Bellicum Pharmaceuticals, JW CreaGene, DanDrit, DCPrime, Elios Therapeutics and ImmunoCellular Therapeutics, etc. In 2024, the global top five players occupied for a share approximately % in terms of revenue.
In United States, in terms of sales revenue, in 2024, the top three players hold a share about %, while in China, top three players hold a share nearly %.
Global Dendritic Cell Cancer Vaccine Scope and Market Size
The global Dendritic Cell Cancer Vaccine market is segmented by company, region (country), type and application. Players, stakeholders, and other participants in the global Dendritic Cell Cancer Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), type and application for the period 2018-2034.
Segment by Type
CreaVax
Sipuleucel-T (Provenge)
Others
Pediatrics
Adults
By Region
United States
Europe
China
Japan
Southeast Asia
India
Other Regions
Activarti
Argos Therapeutics
SOTIO (Acquired by PPF Group)
Bellicum Pharmaceuticals
JW CreaGene
DanDrit
DCPrime
Elios Therapeutics
ImmunoCellular Therapeutics
Kiromic
Medigene
Merck
Northwest Biotherapeutics
Immutep Limited
Dendreon Corporation
Oncobiomed
Dendritic cells (DCs) refer to rare kind of leukocytes. They have prompted their recent application to therapeutic cancer vaccinations as they are uniquely effective in their ability to present antigens to T cells.
Due to the COVID-19 pandemic, the global Dendritic Cell Cancer Vaccine market size is estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034. Fully considering the economic change by this health crisis, CreaVax accounting for % of the Dendritic Cell Cancer Vaccine global market in 2024, is projected to value US$ million by 2034, growing at a revised % CAGR from 2023 to 2034. While Pediatrics segment is altered to an % CAGR throughout this forecast period.
The United States Dendritic Cell Cancer Vaccine market is estimated at US$ million in 2024, while China was US$ million. The proportion of the United States is % in 2024, while Chinese percentage was %, and it is predicted that China share will reach % in 2034, trailing a CAGR of % through the analysis period.
The global key manufacturers of Dendritic Cell Cancer Vaccine include Activarti, Argos Therapeutics, SOTIO (Acquired by PPF Group), Bellicum Pharmaceuticals, JW CreaGene, DanDrit, DCPrime, Elios Therapeutics and ImmunoCellular Therapeutics, etc. In 2024, the global top five players occupied for a share approximately % in terms of revenue.
In United States, in terms of sales revenue, in 2024, the top three players hold a share about %, while in China, top three players hold a share nearly %.
Global Dendritic Cell Cancer Vaccine Scope and Market Size
The global Dendritic Cell Cancer Vaccine market is segmented by company, region (country), type and application. Players, stakeholders, and other participants in the global Dendritic Cell Cancer Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), type and application for the period 2018-2034.
Segment by Type
CreaVax
Sipuleucel-T (Provenge)
Others
Segment by Application
Pediatrics
Adults
By Region
United States
Europe
China
Japan
Southeast Asia
India
Other Regions
By Company
Activarti
Argos Therapeutics
SOTIO (Acquired by PPF Group)
Bellicum Pharmaceuticals
JW CreaGene
DanDrit
DCPrime
Elios Therapeutics
ImmunoCellular Therapeutics
Kiromic
Medigene
Merck
Northwest Biotherapeutics
Immutep Limited
Dendreon Corporation
Oncobiomed
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices